Literature DB >> 12000709

Aberrant methylation of preproenkephalin and p16 genes in pancreatic intraepithelial neoplasia and pancreatic ductal adenocarcinoma.

Noriyoshi Fukushima1, Norihiro Sato, Takashi Ueki, Christophe Rosty, Kimberly M Walter, Robb E Wilentz, Charles J Yeo, Ralph H Hruban, Michael Goggins.   

Abstract

Pancreatic intraductal neoplasia (PanIN) is thought to be the precursor to infiltrating pancreatic ductal adenocarcinoma. We have previously shown that the preproenkephalin (ppENK) and p16 genes are aberrantly methylated in pancreatic adenocarcinoma. In this study we define the methylation status of the ppENK and p16 genes in various grades of PanINs. One hundred seventy-four samples (28 nonneoplastic pancreatic epithelia, 7 reactive epithelia, 29 PanIN-1A, 48 PanIN-1B, 27 PanIN-2, 14 PanIN-3, 15 invasive ductal adenocarcinomas, and 6 miscellaneous pancreatic neoplasms) were microdissected from 29 formalin-fixed paraffin-embedded surgically resected pancreata, and were analyzed by methylation-specific polymerase chain reaction. Fourteen of 15 (93.3%) invasive pancreatic ductal adenocarcinomas showed methylation of the ppENK gene and 4 of 15 (26.7%) showed methylation of the p16 gene. Nonneoplastic pancreatic epithelia did not harbor methylation of either gene. The prevalence of methylation of the ppENK gene increased significantly with increasing PanIN grade. A similar nonsignificant trend was noted for p16 methylation. Aberrant methylation of the ppENK gene was found in 7.7% of PanIN-1A, 7.3% of PanIN-1B, 22.7% of PanIN-2, and 46.2% of PanIN-3. Aberrant methylation of the p16 gene was found in 12% of PanIN-1A, 2.6% of PanIN-1B, 4.5% of PanIN-2, and 21.4% of PanIN-3. All but one of the PanINs from the 14 pancreata without pancreatic carcinoma was unmethylated with respect to either the p16 or ppENK gene. Our results suggest that methylation-related inactivation of the ppENK and p16 genes is an intermediate or late event during pancreatic carcinogenesis. Because aberrant methylation of ppENK or p16 was more often detected in similar grade PanINs from patients with pancreatic carcinoma than in those with other pancreatic diseases, it may be a useful indicator of the potential malignancy of epithelial cells of the pancreas.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12000709      PMCID: PMC1850889          DOI: 10.1016/S0002-9440(10)61104-2

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  32 in total

1.  Accelerated age-related CpG island methylation in ulcerative colitis.

Authors:  J P Issa; N Ahuja; M Toyota; M P Bronner; T A Brentnall
Journal:  Cancer Res       Date:  2001-05-01       Impact factor: 12.701

2.  Aberrant promoter methylation of multiple genes in bronchial brush samples from former cigarette smokers.

Authors:  Jean-Charles Soria; Marivonne Rodriguez; Diane D Liu; J Jack Lee; Waun Ki Hong; Li Mao
Journal:  Cancer Res       Date:  2002-01-15       Impact factor: 12.701

3.  p16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium.

Authors:  D J Wong; T G Paulson; L J Prevo; P C Galipeau; G Longton; P L Blount; B J Reid
Journal:  Cancer Res       Date:  2001-11-15       Impact factor: 12.701

4.  CpG island methylation in premalignant stages of gastric carcinoma.

Authors:  G H Kang; Y H Shim; H Y Jung; W H Kim; J Y Ro; M G Rhyu
Journal:  Cancer Res       Date:  2001-04-01       Impact factor: 12.701

5.  Identification and characterization of differentially methylated CpG islands in pancreatic carcinoma.

Authors:  T Ueki; M Toyota; H Skinner; K M Walter; C J Yeo; J P Issa; R H Hruban; M Goggins
Journal:  Cancer Res       Date:  2001-12-01       Impact factor: 12.701

6.  CpG methylation inhibits proenkephalin gene expression and binding of the transcription factor AP-2.

Authors:  M Comb; H M Goodman
Journal:  Nucleic Acids Res       Date:  1990-07-11       Impact factor: 16.971

7.  Hypermethylation of 14-3-3 sigma (stratifin) is an early event in breast cancer.

Authors:  C B Umbricht; E Evron; E Gabrielson; A Ferguson; J Marks; S Sukumar
Journal:  Oncogene       Date:  2001-06-07       Impact factor: 9.867

8.  Age-related hypermethylation of the 5' region of MLH1 in normal colonic mucosa is associated with microsatellite-unstable colorectal cancer development.

Authors:  H Nakagawa; G J Nuovo; E E Zervos; E W Martin; R Salovaara; L A Aaltonen; A de la Chapelle
Journal:  Cancer Res       Date:  2001-10-01       Impact factor: 12.701

9.  Relation of pancreatic duct hyperplasia to carcinoma.

Authors:  S Kozuka; R Sassa; T Taki; K Masamoto; S Nagasawa; S Saga; K Hasegawa; M Takeuchi
Journal:  Cancer       Date:  1979-04       Impact factor: 6.860

10.  Analysis of K-ras gene mutation in hyperplastic duct cells of the pancreas without pancreatic disease.

Authors:  M Tada; M Ohashi; Y Shiratori; T Okudaira; Y Komatsu; T Kawabe; H Yoshida; R Machinami; K Kishi; M Omata
Journal:  Gastroenterology       Date:  1996-01       Impact factor: 22.682

View more
  62 in total

Review 1.  Molecular signatures of pancreatic cancer.

Authors:  Seung-Mo Hong; Jason Y Park; Ralph H Hruban; Michael Goggins
Journal:  Arch Pathol Lab Med       Date:  2011-06       Impact factor: 5.534

2.  Pancreatic cancer DNMT1 expression and sensitivity to DNMT1 inhibitors.

Authors:  Ang Li; Noriyuki Omura; Seung-Mo Hong; Michael Goggins
Journal:  Cancer Biol Ther       Date:  2010-02-01       Impact factor: 4.742

3.  A Revised Classification System and Recommendations From the Baltimore Consensus Meeting for Neoplastic Precursor Lesions in the Pancreas.

Authors:  Olca Basturk; Seung-Mo Hong; Laura D Wood; N Volkan Adsay; Jorge Albores-Saavedra; Andrew V Biankin; Lodewijk A A Brosens; Noriyoshi Fukushima; Michael Goggins; Ralph H Hruban; Yo Kato; David S Klimstra; Günter Klöppel; Alyssa Krasinskas; Daniel S Longnecker; Hanno Matthaei; G Johan A Offerhaus; Michio Shimizu; Kyoichi Takaori; Benoit Terris; Shinichi Yachida; Irene Esposito; Toru Furukawa
Journal:  Am J Surg Pathol       Date:  2015-12       Impact factor: 6.394

Review 4.  Identifying molecular markers for the early detection of pancreatic neoplasia.

Authors:  Michael Goggins
Journal:  Semin Oncol       Date:  2007-08       Impact factor: 4.929

Review 5.  DNA methylation: its role in cancer development and therapy.

Authors:  Carla Kurkjian; Shivaani Kummar; Anthony J Murgo
Journal:  Curr Probl Cancer       Date:  2008 Sep-Oct       Impact factor: 3.187

6.  Choledochal cyst or pancreatic (retention) cyst: a case report.

Authors:  Jon D Vogel; Charles J Yeo
Journal:  J Gastrointest Surg       Date:  2003 Sep-Oct       Impact factor: 3.452

7.  Genetic analyses of isolated high-grade pancreatic intraepithelial neoplasia (HG-PanIN) reveal paucity of alterations in TP53 and SMAD4.

Authors:  Waki Hosoda; Peter Chianchiano; James F Griffin; Meredith E Pittman; Lodewijk Aa Brosens; Michaël Noë; Jun Yu; Koji Shindo; Masaya Suenaga; Neda Rezaee; Raluca Yonescu; Yi Ning; Jorge Albores-Saavedra; Naohiko Yoshizawa; Kenichi Harada; Akihiko Yoshizawa; Keiji Hanada; Shuji Yonehara; Michio Shimizu; Takeshi Uehara; Jaswinder S Samra; Anthony J Gill; Christopher L Wolfgang; Michael G Goggins; Ralph H Hruban; Laura D Wood
Journal:  J Pathol       Date:  2017-03-30       Impact factor: 7.996

Review 8.  Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine.

Authors:  Erik S Knudsen; Eileen M O'Reilly; Jonathan R Brody; Agnieszka K Witkiewicz
Journal:  Gastroenterology       Date:  2015-09-15       Impact factor: 22.682

Review 9.  Morphogenesis of pancreatic cancer: role of pancreatic intraepithelial neoplasia (PanINs).

Authors:  Jan-Bart M Koorstra; Georg Feldmann; Nils Habbe; Anirban Maitra
Journal:  Langenbecks Arch Surg       Date:  2008-02-19       Impact factor: 3.445

10.  CpG island methylation profile of pancreatic intraepithelial neoplasia.

Authors:  Norihiro Sato; Noriyoshi Fukushima; Ralph H Hruban; Michael Goggins
Journal:  Mod Pathol       Date:  2007-12-21       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.